Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences, Inc.

< Previous 1 2 3 4 5 6 Next >
News headline image
Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Completes Acquisition of AltheaDx
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Acquire AltheaDx
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present at the 24th Annual Needham Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Completes Acquisition of Cernostics
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Named in Inc.’s First-Annual Best-Led Companies
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Named a 2021 Houston Chronicle Top Workplace
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Announces Third Quarter 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
News headline image
Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.